Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

• ClinicalTrials.gov Identifier: NCT05427812
• Recruitment Status: Recruiting
• First Posted: June 22, 2022
• Last Update Posted: June 1, 2023
• Sponsor: Ichnos Sciences SA
• Information provided by (Responsible Party): Ichnos Sciences SA

Study Description

Brief Summary:

This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

Condition or disease	Intervention/treatment	Phase
Relapsed/Refractory Multiple Myeloma	Drug: ISB 1442 SC injection escalating doses; Drug: ISB 1442 SC injection at RP2D	Phase 1; Phase 2

Detailed Description:

The study will be conducted in two phases:

• Phase 1: Dose escalation in R/R MM

• Phase 2: Dose expansions in select R/R MM

  • Cohort A: R/R MM
  • Cohort B: R/R MM Post-T-Cell Directed Therapy Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a Recommended Phase 2 Dose (RP2D) is established in Phase 1 for a given indication, Phase 2 will be initiated for that indication.

Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 121 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a recommended phase 2 Dose (RP2D) is established in Phase 1, Phase 2 will be initiated for that indication. The Phase 2 design uses the Simon two-stage design with stopping rules for lack of activity, as well as stopping rules for toxicity. Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma
• Actual Study Start Date: September 27, 2022
• Estimated Primary Completion Date: May 1, 2027
• Estimated Study Completion Date: May 1, 2027

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase 1: Dose escalation; Participants with R/R multiple myeloma (MM) will be administered ISB 1442 weekly by subcutaneous (SC) injection in each 28-day cycle. Dose escalation will begin with an accelerated titration dose escalation and should certain conversion criteria be met, escalation will convert to the standard (3 + 3) dose escalation	Drug: ISB 1442 SC injection escalating doses; Participants will receive escalating SC doses of ISB 1442
Experimental: Phase 2 (Dose Expansion): Cohort A: R/R Multiple Myeloma; This cohort includes the participants with pathologically confirmed R/R MM and must have received at least 3 prior lines of therapy, including proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. Participants will receive the recommended Phase 2 Dose (RP2D) of ISB 1442 SC injection determined in Phase 1 of the study for treatment of R/R MM. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.	Drug: ISB 1442 SC injection at RP2D; ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
Experimental: Phase 2 (Dose Expansion): Cohort B: R/R MM Post-T-cell-Directed Therapy; This cohort includes the participants with pathologically confirmed R/R MM post T cell-directed therapy and have received prior treatment with proteasome inhibitors (PIs), immunomodulators (IMiDs), and anti-CD38 therapies either in combination or as a single agent; and must have failed at least 3 prior lines of treatment. Participants will receive the RP2D of ISB 1442 SC injection determined in Phase 1 of the study. Each treatment cycle duration is 28 days. The anticipated total duration for each participant will vary, depending on the number of cycles of treatment completed. The treatment phase will extend until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met.	Drug: ISB 1442 SC injection at RP2D; ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met

Outcome Measures

Primary Outcome Measures :

1. Phase 1: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Up to 18 months ]
2. Phase 1: Number of Dose-Limiting Toxicities (DLTS) During the First 28 Days After the First Administration of ISB 1442 (Cycle 1) [ Time Frame: Up to 28 days ]
3. Phase 2: Multiple Myeloma: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG) [ Time Frame: 18 months ]

Secondary Outcome Measures :

1. Maximum Concentration (Cmax) of ISB 1442 in Serum [ Time Frame: Up to 28 days ]
2. Time to Reach Maximum Concentration (Tmax) of ISB 1442 in Serum [ Time Frame: Up to 28 days ]
3. Area Under the Concentration Time Curve From Zero to Time t (AUC0-t) of ISB 1442 in Serum [ Time Frame: Up to 28 days ]
4. Area Under the Concentration Time Curve in Dosing Intervals (AUC0-tau) of ISB1442 in Serum [ Time Frame: Up to 28 days ]
5. Percent Incidence of Anti-Drug Antibody (ADA) and Neutralizing Antibody (nAb) From Baseline Until End-of-Treatment (EOT) [ Time Frame: Baseline to 18 months ]
6. Phase 1 and Phase 2: Time to Progression (TTP) [ Time Frame: 18 Months ]
7. Phase 1 and Phase 2: Time to Next Treatment (TTNT) [ Time Frame: 18 Months ]
8. Phase 1 and Phase 2: Time to Response (TTR) [ Time Frame: 18 Months ]
9. Phase 1 and Phase 2: Progression free survival (PFS) [ Time Frame: 18 Months ]
10. Phase 1 and Phase 2: Overall survival (OS) [ Time Frame: 18 Months ]
11. Phase 1: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG) [ Time Frame: 18 months ]
12. Phase 1 and Phase 2: Complete Response Rate (CRR) Based on International Myeloma Working Group (IMWG) [ Time Frame: 18 months ]
13. Phase 1 and Phase 2: Duration of Response (DOR) Based on International Myeloma Working Group (IMWG) [ Time Frame: 18 months ]
14. Phase 2: Frequency and Severity of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: 18 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female patients aged 18 years or older.
2. Be willing and able to provide written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act of 1996 [HIPAA]) prior to any protocol related procedures, including screening evaluations

3. Phase 1: Patients with pathologically confirmed multiple myeloma (MM) who have progressed on or after standard therapy (relapsed/refractory [R/R] patients):

   1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. (Note: Patients in Australia may have received any of the therapies including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit ).
   2. Must have measurable M-protein (serum and/or 24-hr urine, or serum free light chains).

4. Phase 2: Patients with pathologically confirmed MM who have progressed on or after standard therapy (R/R patients):

   Cohort A: R/R MM

   1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent;

   2. Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria):

      • Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or
      • Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or
      • Serum free light chain (sFLC) assay: involved free light chain (FLC) level ≥ 10 mg/dL provided sFLC ratio is abnormal.

   Cohort B: R/R MM Post-T-Cell Directed Therapy

   1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs and anti-CD38 therapies either in combination or as a single agent; and have relapsed and/or be refractory to a T-cell directed therapy including cellular therapies or T cell engagers.

   2. Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria):

      • Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or
      • Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or
      • sFLC assay: involved FLC level ≥ 10 mg/dL provided sFLC ratio is abnormal
5. Have a body weight ≥ 40.0 kg at screening.
6. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
7. Have life expectancy of at least 3 months (from date of informed consent signing).

8. Have adequate organ function, including:

   1. Aspartate aminotransferase (AST, GOT) and alanine aminotransferase (ALT, GPT) ≤3.0 × ULN; bilirubin ≤1.5 × ULN. Patients with Gilbert's syndrome may have a bilirubin level >1.5 × ULN, per discussion between the Investigator and medical monitor.
   2. Estimated creatinine clearance ≥45 mL/min as calculated using the Cockcroft-Gault formula or 24-hour urine collection.
9. Left ventricular ejection fraction (LVEF) ≥45% as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan.

Exclusion Criteria:

1. Participants with relapsed disease where relapse is characterized only by minimal residual disease parameters (i.e., minimal residual disease positive).
2. Participants with MM with disease where the only measurable parameter is plasmacytoma.
3. Received treatment with anti-CD38 antibodies or CD47 targeted therapies within 1 month of C1D1; systemic anticancer treatments within 14 days before the first dose of study drug (C1D1) or any investigational products within 5 half-lives of C1D1, whichever is appropriate to last therapy received. (eg, non-IMP IMiD, proteasome inhibitor could be considered to be eligible if there is at least 14 days after last dose before C1D1. Note: Treatment with a single course of glucocorticoids is allowed (maximum dose of corticosteroids should not exceed the equivalent of 160 mg [for example, 40 mg/d for 4 days] of dexamethasone). Hormonal therapy for prostate cancer or breast cancer (as adjuvant treatment), and treatment with bisphosphonates and receptor activator of nuclear factor kappa-Β ligand inhibitors are allowed.
4. Received autologous stem cell transplantation within 12 weeks of C1D1.
5. Current participation in another interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) within 4 weeks of C1D1 and throughout the duration of this trial.
6. Prior radiation therapy within 14 days of C1D1; or prior irradiation to > 25% of the bone marrow. Note: Prophylactic localized ("spot") radiation for areas of pain is allowed.
7. Active malignant central nervous system involvement
8. Known to be refractory to platelet or RBC transfusions
9. Known severe allergic or anaphylactic reactions to human recombinant proteins or excipients used in the ISB 1442 formulation.
10. QTc interval > 480 msec at screening using Fredericia's QT correction formula.

Contacts and Locations

Contacts

Contact: Ichnos Sciences Clinical Trials Administrator; (315) 583-1249; clinicaltrials@ichnossciences.com

Locations

United States, Florida

University of Miami - Sylvester Comprehensive Cancer Center; Recruiting

Miami, Florida, United States, 33136

Contact: Dickran G. Kazandjian, MD dkazandjian@miami.edu

United States, Illinois

The University of Chicago Medical Center (UCMC) Duchossois Center for Advanced Medicine (DCAM); Not yet recruiting

Chicago, Illinois, United States, 60637

Contact: Benjamin Derman, MD bderman@bsd.uchicago.edu

United States, Michigan

Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus; Not yet recruiting

Detroit, Michigan, United States, 48201

Contact: Jeffrey Zonder, MD zonderj@karmanos.org

United States, Missouri

Washington University School of Medicine - Siteman Cancer Center; Recruiting

Saint Louis, Missouri, United States, 63110

Contact: Mark Schroeder, MD markschroeder@wustl.edu

United States, New York

New York-Presbyterian /Weill Cornell Medical Center - The Myeloma Center; Not yet recruiting

New York, New York, United States, 10065

Contact: Ruben Niesvizky, MD run9001@med.cornell.edu

United States, Wisconsin

Froedtert Hospital & The Medical College of Wisconsin; Recruiting

Milwaukee, Wisconsin, United States, 53226

Contact: Binod Dhakal, MD bdhakal@mcw.edu

Australia, New South Wales

Royal Prince Albert Hospital: Institute of Haematology; Recruiting

Camperdown, New South Wales, Australia, 2050

Contact: Jo Ho, MBBS,D.Phil,FRACP,FRCPA,FFSc joy.ho1@health.nsw.gov.au

Australia, Queensland

Pindara Private Hospital; Recruiting

Benowa, Queensland, Australia, 4217

Contact: Hanlon Sia, MBBS(Adelaide), FRACP, FRCPA hanlonsia@yahoo.com.au

Gold Coast University Hospital; Recruiting

Southport, Queensland, Australia, 4211

Contact: Tara Cochrane, MD tara.cochrane@health.qld.gov.au

Australia, Victoria

St. Vincent's Hospital Melbourne; Recruiting

Fitzroy, Victoria, Australia, 3065

Contact: Hang Ai Quach, MD hang.quach@svha.org.au

The Alfred Hospital-Melbourne; Recruiting

Melbourne, Victoria, Australia, 3004

Contact: Andrew Spencer, MBBS FRACP FRCPA DM andrew.spencer@monash.edu

Australia, Western Australia

One Clinical Research Pty Ltd; Recruiting

Nedlands, Western Australia, Australia, 6009

Contact: Peter Tan, MBBS(Hons),MPhil,FRACP,FRCPA peter.tan@oneclinicalresearch.com.au

Sponsors and Collaborators

Ichnos Sciences SA

More Information

• Responsible Party: Ichnos Sciences SA
• ClinicalTrials.gov Identifier: NCT05427812
• Other Study ID Numbers: ISB 1442-101
• First Posted: June 22, 2022
• Last Update Posted: June 1, 2023
• Last Verified: May 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ichnos Sciences SA:

Open-label; dose-escalation; dose-expansion; ISB 1442; relapsed/refractory multiple myeloma

Additional relevant MeSH terms:

Multiple Myeloma; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases